The Californian company's first commercial product, Phexxi (lactic acid, citric acid and potassium bitartrate), is the first and only vaginal pH regulator approved in the USA for the prevention of pregnancy.

Evofem is also advancing EVO100 into Phase III trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women.